Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2141.2012.09189.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipid core-chitosan shell hybrid nanoparticles for enhanced oral bioavailability of sorafenib.
Int J Biol Macromol
January 2025
College of Pharmacy, Institute of Pharmaceutical Sciences and Technology, Hanyang University ERICA, Ansan 15588, Republic of Korea. Electronic address:
Limited aqueous solubility is a major hurdle resulting in poor and variable oral bioavailability, high doses, side effects, and the suboptimal therapeutic efficacy of sorafenib (SRF). In this study, we developed SRF-loaded solid lipid nanoparticles (SRF-SLNs) and lipid core-chitosan shell hybrid nanoparticles (CS-SRF-SLNs) to improve the oral absorption of SRF. SRF-SLNs were prepared using a stearyl alcohol core stabilized with a surfactant mixture, followed by surface decoration with chitosan to form CS-SRF-SLNs.
View Article and Find Full Text PDFanalysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells.
World J Gastroenterol
January 2025
Department of Oncology Surgery, Cell Therapy and Organ Transplantation, Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, Seville 41013, Spain.
Background: Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer with varied incidence and epidemiology worldwide. Sorafenib is still a recommended treatment for a large proportion of patients with advanced HCC. Different patterns of treatment responsiveness have been identified in differentiated hepatoblastoma HepG2 cells and metastatic HCC SNU449 cells.
View Article and Find Full Text PDFThe Combined Impact of Curcumin: Piperine and Sorafenib on microRNAs and Different Pathways in Breast Cancer Cells.
Indian J Clin Biochem
January 2025
Hormones Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Unlabelled: Breast cancer is the most common malignancy in the women. Chemotherapy is a crucial part of breast cancer treatment especially for advanced and metastatic forms of the disease. However, chemotherapy has limitations due to tumor heterogeneity, chemoresistance, and side effects.
View Article and Find Full Text PDFTargeting estrogen-regulated system x promotes ferroptosis and endocrine sensitivity of ER+ breast cancer.
Cell Death Dis
January 2025
Wenzhou Key Laboratory of Cancer Pathogenesis and Translation, Key Laboratory of Laboratory Medicine, School of Laboratory Medicine and Life Sciences, Ministry of Education, Wenzhou Medical University, 325035, Wenzhou, China.
Estrogen receptor positive (ER+) breast cancer accounts for approximately 70% of cases. Endocrine therapies targeting estrogen are the first line therapies for ER+ breast cancer. However, resistance to these therapies occurs in about half of patients, leading to decreased survival rates.
View Article and Find Full Text PDFSelf-Assembly Nanomedicine Initiating Cancer-Immunity Cycle with Cascade Reactions for Boosted Immunotherapy.
Chem Eng J
January 2025
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.
Immune checkpoint blockade (ICB) therapy has been extensively integrated into cancer clinical management. However, its overall response rate is limited due to the stagnating cancer-immunity cycle (CIC) caused by the immunosuppressive tumor microenvironment (TME). Here, a multi-pronged nanomedicine, defined as LCCS, was constructed by the self-assembly of lactate oxidase, catalase, chlorin e6, and sorafenib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!